ABCL — AbCellera Biologics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703057 ·
Last close
$5.71
Market Cap
$1.74B
52W High
$8.44
52W Low
$3.94
ADV30
6,967,719
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,315,000 | — | -53,180,000 | -43,165,000 | 1,307,112,000 | 77,063,000 | 369,029,000 |
| Dec 2025 | 44,853,000 | — | -25,266,000 | -8,945,000 | 1,356,950,000 | 128,513,000 | 390,046,000 |
| Sep 2025 | 8,955,000 | — | -73,549,000 | -57,119,000 | 1,355,992,000 | 83,159,000 | 391,954,000 |
| Jun 2025 | 17,084,000 | — | -45,893,000 | -34,727,000 | 1,402,061,000 | 92,437,000 | 394,985,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-153,264,000
Investing CF
$54,734,000
Financing CF
$15,304,000
CapEx
$-35,967,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,647,000
Inventory
$7,860,000
Receivables
$115,725,000
ST Investments
$427,669,000
EBIT TTM
$-197,888,000
Pretax Income TTM
$-174,148,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,208,000
EBITDA
$-188,284,000
Free Cash Flow
$-114,039,248
Enterprise Value
$1,373,031,936
Total Cash
$504,732,000
Total Debt
$140,178,000
Shares Out
305,375,393
Trailing EPS
$-0.48
Book Value
$3.09
ROE
-14.7%
ROA
-10.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,128,000 | -203,213,000 | -146,412,000 | 1,356,950,000 | 390,046,000 | — | -131,295,000 |
| Dec 2024 | 28,833,000 | -301,146,000 | -162,857,000 | 1,360,553,000 | 304,469,000 | — | -108,556,000 |
| Dec 2023 | 38,025,000 | -223,052,000 | -146,398,000 | 1,488,094,000 | 335,776,000 | — | -43,877,000 |
| Dec 2022 | 485,424,000 | 227,065,000 | 158,519,000 | 1,540,907,000 | 307,630,000 | — | 277,360,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$107,890,000
NetIncome TTM
$-24,483,000
OpCashFlow TTM
$0
Assets (Latest)
$1,360,553,000
Forward EPS
$-0.72
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | $1.78B | $27.10 | — |
| DMRA | Damora Therapeutics, Inc. | $1.78B | $28.99 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $30.02 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.79B | $8.17 | — |
| GENB | Generate Biomedicines, Inc. | $1.79B | $14.00 | — |
News headlines (Yahoo Finance, 1h cache)
Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?
2026-07-29 19:08 · Yahoo
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
2026-07-29 11:00 · Yahoo
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
2026-07-15 12:45 · Yahoo
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-07 20:05 · Yahoo
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
2026-07-07 16:00 · Yahoo
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
2026-07-06 13:00 · Yahoo
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
2026-07-03 13:40 · Yahoo
Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside?
2026-07-01 21:23 · Yahoo
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
2026-06-29 03:56 · Yahoo
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
2026-06-25 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.